TY - JOUR
T1 - Incidence of chemotherapy-induced peripheral neuropathy within 12 weeks of starting neurotoxic chemotherapy for multiple myeloma or lymphoma
T2 - a prospective, single-center, observational study
AU - Ajewole, Veronica B.
AU - Cox, James E.
AU - Swan, Joshua T.
AU - Chikermane, Soumya G.
AU - Lamoth, Beverly
AU - Iso, Tomona
AU - Okolo, Laura O.
AU - Ford, Christen L.
AU - Schneider, Amy M.
AU - Hobaugh, Eleanor C.
AU - Baker, Kelty R.
N1 - Funding Information:
The authors would like to thank Drs. Lawrence Rice, Swaminathan Iyer, Ibrahim Ibrahim, Sai Ravi Pingali, Kirk Heyne, and Eric Bernicker Hematology/Oncology Physicians at Houston Methodist Hospital for giving the investigators permission to approach their patients for enrollment in this study. The authors would like to thank Marcus Scott, infusion clinic scheduler, and David Raven, RN, at Houston Methodist Hospital, for helping with patient identification. A research poster containing study results were presented at the Vizient? Pharmacy Network meeting in Las Vegas, Nevada, in December 2016. A research poster was presented at the Hematology/Oncology Pharmacy Association Conference in Anaheim, CA, in March 2017. A platform presentation of study results was presented at the Midwest Pharmacy Residency Conference in Omaha, NE, in May 2017.
Publisher Copyright:
© 2019, Springer-Verlag GmbH Germany, part of Springer Nature.
Copyright:
Copyright 2020 Elsevier B.V., All rights reserved.
PY - 2020/4/1
Y1 - 2020/4/1
N2 - Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) may necessitate chemotherapy dose reduction, delay, or discontinuation. This pilot study tested feasibility of patient enrollment, CIPN screening, and data collection in cancer patients for a future clinical study that will assess the safety and efficacy of an intervention that may prevent CIPN. Methods: This prospective, observational, single-center, pilot study included adults with newly diagnosed lymphoma or multiple myeloma receiving neurotoxic chemotherapy. Patients were enrolled between September 2016 and February 2017. The Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire was completed by patients at 3 time points: baseline, week 6, and week 12. The primary outcome was change in the neurotoxicity score between these time points. Results: Of 33 patients approached for consent, 28 (85%) provided consent and were enrolled. The FACT/GOG-Ntx questionnaire was completed by 28 (100%) at baseline, 25 (89%) at week 6, and 24 (86%) at week 12. Average (standard deviation) neurotoxicity scores were 36.5 (6.6) at baseline, 34.0 (8.3) at week 6, and 30.6 (7.6) at week 12. Neurotoxicity scores changed from baseline by − 2.7 points (95% CI − 5.5 to 0.1; p = 0.061) at week 6 and − 6.0 points (95% CI − 5.6 to − 0.8; p = 0.012) at week 12. Clinically meaningful declines (decrease of > 10% from baseline) in neurotoxicity score were detected in 36% (9 of 25) at week 6 and in 67% (16 of 24) at week 12. Conclusion: Sixty-seven percent of patients experienced clinically significant CIPN within 12 weeks of starting chemotherapy. Feasibility metrics for enrollment, consent, CIPN assessment, and follow-up were met.
AB - Purpose: Chemotherapy-induced peripheral neuropathy (CIPN) may necessitate chemotherapy dose reduction, delay, or discontinuation. This pilot study tested feasibility of patient enrollment, CIPN screening, and data collection in cancer patients for a future clinical study that will assess the safety and efficacy of an intervention that may prevent CIPN. Methods: This prospective, observational, single-center, pilot study included adults with newly diagnosed lymphoma or multiple myeloma receiving neurotoxic chemotherapy. Patients were enrolled between September 2016 and February 2017. The Functional Assessment of Cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx) questionnaire was completed by patients at 3 time points: baseline, week 6, and week 12. The primary outcome was change in the neurotoxicity score between these time points. Results: Of 33 patients approached for consent, 28 (85%) provided consent and were enrolled. The FACT/GOG-Ntx questionnaire was completed by 28 (100%) at baseline, 25 (89%) at week 6, and 24 (86%) at week 12. Average (standard deviation) neurotoxicity scores were 36.5 (6.6) at baseline, 34.0 (8.3) at week 6, and 30.6 (7.6) at week 12. Neurotoxicity scores changed from baseline by − 2.7 points (95% CI − 5.5 to 0.1; p = 0.061) at week 6 and − 6.0 points (95% CI − 5.6 to − 0.8; p = 0.012) at week 12. Clinically meaningful declines (decrease of > 10% from baseline) in neurotoxicity score were detected in 36% (9 of 25) at week 6 and in 67% (16 of 24) at week 12. Conclusion: Sixty-seven percent of patients experienced clinically significant CIPN within 12 weeks of starting chemotherapy. Feasibility metrics for enrollment, consent, CIPN assessment, and follow-up were met.
KW - Alpha lipoic acid
KW - Chemotherapy-induced peripheral neuropathy (CIPN)
KW - Functional Assessment of cancer Therapy/Gynecologic Oncology Group-Neurotoxicity (FACT/GOG-Ntx)
KW - Lymphoma
KW - Myeloma
KW - Over-the-counter (OTC)
KW - Pyridoxine (vitamin B6)
KW - Thiamine (vitamin B1)
UR - http://www.scopus.com/inward/record.url?scp=85069916138&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85069916138&partnerID=8YFLogxK
U2 - 10.1007/s00520-019-05006-6
DO - 10.1007/s00520-019-05006-6
M3 - Article
C2 - 31359183
AN - SCOPUS:85069916138
VL - 28
SP - 1901
EP - 1912
JO - Supportive Care in Cancer
JF - Supportive Care in Cancer
SN - 0941-4355
IS - 4
ER -